Background: An investigation of safety issues regarding information on contraindications related to cross allergy was conducted to promote clinical awareness and prevent medical errors in a 2200-bed tertiary care teaching hospital. Methods: Prescribing information on contraindications concerning cross allergy was collected from an information system and package inserts. Data mining and descriptive analysis were performed. A risk register was used for project management and risk assessment. A Plan, Do, Check, Act cycle was used as part of continuous quality improvement. Records of drug counseling and medical errors were collected from an online reporting system. A pharmacist-led multidisciplinary team initiated an intervention program on cross allergy in August 2008. Results: Four years of risk management at our hospital achieved successful outcomes, ie, the number of medical errors related to cross allergies decreased by 97% (10 cases monthly before August 2008 versus three cases yearly in 2012) and risk rating decreased significantly [initial risk rating: 25(high-risk) before August 2008 versus final risk rating:6 (medium-risk) in December 2012]. Conclusion: We conclude that comprehensive clinical interventions are very effective through team cooperation. Medication use has potential for safety risks if sufficient attention is not paid to contraindications concerning cross allergy. The potential for cross allergy involving drugs which belong to completely different pharmacological classes is easily overlooked and can be dangerous. Pharmacists can play an important role in reducing the risk of cross allergy as well as recommending therapeutic alternatives.
Introduction
A drug allergy is an immunologically mediated reaction that exhibits specificity and recurrence on re-exposure to the offending drug. It occurs in 1%-2% of all admissions and 3%-5% of hospitalized patients. 1 Allergic drug reactions account for 5%-10% of all adverse drug reactions and have the potential to cause harm to patients. 2 However, allergies can be prevented if the patient's history of drug allergy is known and coded. 3, 4 To guarantee safety in medication use, the Joint Commission International requires that a detailed drug allergy history should take into account when doctors prescribe drugs and pharmacists dispense them. 5 Furthermore, a patient who is allergic to one specific drug may be allergic to other drugs of similar chemical structure. That is known as cross allergy or cross sensitivity.
Some patients who have a sensitized reaction to medications like nonsteroidal anti-inflammatory drugs (NSAIDs) may have trouble taking any drug belonging to that class, and doctors should try other medications first to avoid cross allergy. For example, acetaminophen which shares the analgesic and antipyretic properties of the NSAIDs, can be used for a patient who is running a high fever but has a history of allergy to NSAIDs. If this step is overlooked, pharmacists can still help detect problems with cross sensitivity if they have a clear understanding of what is being prescribed. Therefore, communication and team cooperation between patients, doctors, pharmacists, nurses, and information engineers are very important for safety assurance.
Overlooking the issue of cross allergy may cause medication errors. However, many doctors, nurses, and pharmacists only focus on cross allergy involving drugs within the same therapeutic class, such as NSAIDs, and may not pay enough attention to cross allergies occurring when, for example, two drugs belonging to a completely different pharmacological class can provoke cross sensitivity as a result of a particular formulation excipient in common.
Four years ago, a serious medication error occurred at our hospital in a female cancer patient with a history of allergy to procaine, a local anesthetic. She was receiving intravenous metoclopramide to avoid possible chemotherapyinduced vomiting. When her daughter was reading the package insert for metoclopramide, she noticed that the drug is contraindicated in patients with a history of allergy to procaine. Immediately a senior clinical pharmacist was consulted. The dispensing pharmacist had not been aware of this type of cross allergy because the two drugs were so different in their therapeutic action. Fortunately, the patient did not experience any adverse drug reaction, and although she forgave our medical staff, the case taught us a profound lesson. Subsequently, a systematic investigation was undertaken of prescribing information on contraindications related to cross allergy for all medications used in our hospital and preliminary interventions were implemented, as discussed here.
Materials and methods

Data collection
This investigation was performed at the Second Affiliated Hospital, School of Medicine, Zhejiang University. The hospital has 2200 beds, with 2.7 million outpatient visits made annually. A conditional search was performed for each drug using the "New Clinical Drug Reference" software jointly developed by Beijing Kingyee Technology Co, Ltd. and the Chinese Pharmaceutical Association (http://www. medscape.com.cn). An informatics pharmacist recorded any information on contraindications related to cross allergy. Full prescribing information for each medication used in the hospital was reviewed for verification. The cross allergy issue was addressed by retrieving all records from drug counseling, medical consultations, and our online no-fault reporting system which accepts reports of adverse events and medication errors from medical staff. A causality assessment of drug allergy was carried out using the adverse reactions probability scale devised by Naranjo et al. 8 
Risk register and intervention procedure
A risk register, a tool commonly used in project management and organizational risk assessments, 9 was used for prevention of cross allergy. A pharmacist-led multidisciplinary team initiated an intervention program on cross allergy in August 2008. The clinical intervention measures and risk reduction strategies are described in Table 1 . Risk likelihood was divided into five levels, ie, almost certain (at least weekly, score 5), likely (monthly, score 4), possible (quarterly, score 3), unlikely (may occur every year, score 2), and remote (may occur every 2 years or more, score 1). Consequences were divided into five grades, ie, extreme (score 5), major (score 4), moderate (score 3), minor (score 2), and insignificant (score 1).
Statistical analysis
A descriptive analysis was performed. According to the Hong Kong Hospital Authority risk quantification matrix and risk register documents, the risk rating is derived from likelihood multiplied by consequences, and the value divided into three risk grades (ie, high risk, $16; medium risk, 6-15; low risk, 1-5). 11 The percentage of questions on cross allergy correctly answered the first time by pharmacists was calculated by correct responses in the first instance divided by all responses. • Doctors must record any real or potential allergies or sensitivities in the electronic medical record which occurred prior to admission or during hospitalization.
• Implement maintenance of pharmacy storehouse information management subsystem. For example, a warning that "Patients who are allergic to an aminoglycoside antibiotic should not receive any aminoglycosides" will appear when doctors prescribe isepamicin for patients with a history of allergy to amikacin.
• Publish a standard operating procedure for drug allergy management and an updated list of medications associated with cross allergy in the local area network. Series of academic lectures, especially typical case analysis, arranged for medical staff.
• Note skin test results when physicians prescribe special medications for patients. For example, a prescription of penicillamine should contain descriptions of "skin test exemption" or "skin test negative". Otherwise, the prescription will be intercepted by auditing pharmacists.
• Adopt a pragmatic approach to use of beta-lactams in patients with penicillin allergy.
• Install an online database embedded in the hospital information system and electronic medical record system. The database, named the Clinical Medication Decision Support System, was developed by Elsevier Datong (http://www.clinicaldecisionsupport.com.cn), and can effectively detect contraindications related to cross allergy.
• Software modification was implemented to overcome an information design defect, ie, the interface of the pharmacy management information system could not show the records of drug allergy (eg, allergy history, medication name, clinical manifestations) so that pharmacists could not detect severe pharmacotherapeutic issues in the dispensing process.
• Implementation of an intrahospital pharmacovigilance system notifying all medical staff when a cross allergy occurs in the hospital.
• Medical staff are encouraged to report any medication errors via a specific spontaneous reporting system. A Plan, Do, Check, Act cycle is built into ongoing quality improvement. Prescribing information for certain drugs clearly notes that they are contraindicated in patients who are allergic to drugs belonging to other therapeutic classes. Further, information on contraindications for some drugs which belong to completely different therapeutic classes clearly notes that they are contraindicated in patients who are allergic to structurally similar classes (Table 3 ). Formulation excipients that provoke cross sensitivity are listed in Table 4 .
Information on contraindications related to cross allergy for some drugs does not provide direct guidance on safe use of such medication. Four drugs with inadequate information were identified, comprising: donepezil, which is contraindicated in patients who are allergic to piperidine derivatives; diacerein, which is contraindicated in patients who are allergic to anthraquinone derivatives; bifonazole cream, which is contraindicated in patients who are allergic to imidazoles; and doxofylline, which is contraindicated in patients who are allergic to xanthine derivatives.
Effects of intervention
The outcomes of reducing the risk of cross allergy are shown in Table 5 , and indicate that our four-year comprehensive clinical intervention through team cooperation was very effective.
Discussion
Descriptions of cross allergy in information on contraindications for drugs within the same pharmacological class were usually consistent. However, inconsistent descriptions were noted for partial agonists, including organic nitrates, angiotensinconverting enzyme inhibitors, local anesthetics, retinoids, 5-HT3 receptor antagonists, and bisphosphonates (Table 2) . To our knowledge, this is a completely new finding and indicates that doctors and pharmacists should carefully select an alternative for patients who are allergic to certain drugs. For example, oral tretinoin and viaminate, instead of acitretin, can The six kinds of drugs belong to different therapeutic classes, but the contraindication information for these drugs all indicates that they are contraindicated in patients who are allergic to sulfonamides. Even for drugs that share the same generic name but have different manufacturers, it is possible to find different descriptions in the information on contraindications, as noted for oxaliplatin ( Table 2 ). The product manufactured domestically is contraindicated in patients who are allergic to platinum derivatives, whereas the information on contraindications for the original imported product contains no mention of cross allergy. To avoid medico-legal disputes between physicians and patients, it is relatively safe to prescribe the original imported product of oxaliplatin instead of domestic oxaliplatin for patients who are allergic to platinum derivatives. An evidence-based meta-analysis indicates that special emphasis should be placed on the role of chemical structure in determining the risk of cross-reactivity between specific agents. There are practical differences between the professions of medicine and pharmacy, the most obvious one being that the pharmacist has a more indepth understanding of pharmaceutical chemistry. Theoretically, an educational background in pharmaceutical chemistry means that pharmacists have a relatively higher degree of knowledge about cross allergy than doctors or nurses. Therefore, it is necessary for pharmacists to lead the relevant clinical interventions. Pharmacists can play an important role in detecting problems with cross allergy, and are often at the point of care where decisions about cross allergy can impact selection of medication, so they can assist by recommending alternatives. 13 As an example, in 2011 we handled a successful case involving an elderly female patient suffering from a urinary tract infection who visited our hospital and was found to be allergic to a cephalosporin. She had previously received fluoroquinolone therapy, but the therapeutic effect was very poor. Urine bacterial culture results indicated infection with extended-spectrum beta-lactamase-producing Escherichia coli. The doctor asked a clinical pharmacist for suggestions. Generally, piperacillintazobactam and cephamycins, instead of fluoroquinolones, cephalosporins, aminoglycosides, and oxacephems, are used for treatment of mild to moderate infection caused by extended-spectrum beta-lactamase-producing E. coli. 14 However, a patient with a history of allergy to a cephalosporin should not receive fourth-generation cephalosporins, atypical β-lactams (eg, cefoxitin, cefminox, latamoxef), or combination β-lactamase formulations such as piperacillin-tazobactam. Taking into consideration bacterial resistance, the antimicrobial spectrum, and the cross allergy issue, the pharmacist finally recommended intravenous cefmetazole and oral furadantine as alternatives. Interestingly, no obvious information on cross allergy involving drugs belonging to completely different pharmacological classes appeared in the package inserts. For example, information on contraindications for vancomycin mentions that the drug should not be prescribed for patients who are allergic to glycopeptide antibiotics and aminoglycosides. However, the information on contraindications for aminoglycosides does not note cross allergy related to vancomycin. Metoclopramide is contraindicated in patients who are allergic to procaine and procainamide, whereas the information on contraindications for procaine and procainamide do not note cross allergy in relation to metoclopramide. Almost all doctors, pharmacists, and nurses did not know this important information before Figure 1 . Procaine carries an ester moiety whereas metoclopramide and procainamide carry an amide moiety. Ester and amide are mutual isosteres, so may share the same cross-reactivity pattern, just like amide-type lidocaine and ester-type procaine. A case of immunoglobulin E-mediated anaphylaxis induced by metoclopramide has been documented. 15 Therefore, doctors need to take a careful patient history of allergy and select an appropriate medication prior to initiating treatment of nausea and vomiting for patients who are allergic to procaine.
Sometimes information on contraindications gives descriptions of cross allergy related to formulation excipients. However, this aspect seems of less concern to clinicians.
Paclitaxel containing Cremophor is contraindicated in patients with a history of allergy to polyoxyethylene castor oil. However, the prescribing information on contraindications for nanoparticle albumin-bound formulations does not note any cross allergy issues. Therefore, this novel formulation of paclitaxel may have certain advantages. 16 Some descriptions are so unintelligible and obscure that they lack practical value in guiding safe use of medication, and can cause tension between doctor and patient. For example, Aricept ® (donepezil hydrochloride, Eisai Inc, Woodcliff Lake, NJ, USA), a drug widely used in the treatment of Alzheimer's disease, is contraindicated in patients with known hypersensitivity to donepezil hydrochloride or to piperidine derivatives. However, very few hospital staff except pharmaceutical chemists would know which drugs are piperidine derivatives. Such a description may help to understand an allergy that has already happened, but has a limited role in preventing cross allergy, so there is a need to standardize further the information on contraindications related to cross allergy, including specific structural chemical classes, in the future.
A good medication history should encompass all currently and recently prescribed drugs, previous adverse drug events, including hypersensitivity reactions, any over-the counter medications, including herbal or alternative medicines, and adherence with therapy. Documentation of allergies occurring during medical admissions is also very necessary, but hypersensitivity reactions are often poorly documented or not explored in detail, which may lead to potential cross allergy. 17 Bruce Bayley et al introduced a medication reconciliation service and recommended identification of allergy as a key contribution at admission and in the follow-up plan at discharge. 18 Barton et al reported that involvement of clinical pharmacists leads to improved documentation. 19 We introduced a tracer methodology and a work pattern of pharmacist review to address the problem. Collaboration among doctors, nurses, pharmacists, and information engineers is very important. Integration of our clinical information system technology, including computerized entry of physician orders, pharmacy and laboratory information systems, clinical decision support systems, an electronic drug dispensing system, and a bar code point-of-care medication administration system decreased medication errors involving cross allergy. Multidisciplinary teams provide a vital safety net for their patients and colleagues. 20 
Conclusion
Use of medication can be potentially hazardous if adequate attention is not paid to information on contraindications 
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Therapeutics and Clinical Risk Management 2013:9 related to cross allergy. A systematic investigation of this problem was undertaken in a 2200-bed tertiary care teaching hospital. A pharmacist-led multidisciplinary team initiated an intervention program on cross allergy at our institution, and a risk register was used in the management of this project. Four years of experience in risk management at our hospital indicates that comprehensive clinical intervention including team cooperation can play an important role in detecting problems with cross allergy as well as the ability to recommend safer alternatives.
